ER
FLXN

Enlightenment Research’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Enlightenment Research’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$6K – 759
2018
Q4 		$6K Buy
+500
New +$7.84K 0.01% 679

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Enlightenment Research's FLXN Position: Q1 2019 in Review

Enlightenment Research sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2019, closing a stake of 500 shares — an estimated $6K sold.

Enlightenment Research first reported a position in FLXN in Q4 2018 and held it in 1 quarter. The position peaked at $6K in Q4 2018. 129 funds tracked by Wall St. Rank hold FLXN as of Q1 2019.

  • Enlightenment Research reported no remaining Flexion Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 500 Flexion Therapeutics, Inc. shares in Q1 2019, an estimated $6K.
  • Enlightenment Research first reported a position in Flexion Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Flexion Therapeutics, Inc. position peaked at $6K in Q4 2018.
  • 129 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.